Adenosine analogues and their use as pharmaceutical agents

A compound according to formula (I)

• wherein:
• W is N or N→O;
• Q is CH2;
• R1 is selected from the group consisting of hydrogen, C1-C10-alkyl, allyl, 2-methylallyl, 2-butenyl and C1-C10-cycloalkyl;
• X is selected from the group consisting of
• wherein n and p are independently 0, 1, 2, or 3, provided that n+p is at least 1;
• and unsubstituted and at least monosubstituted C1-C10-alkylene-Y, C2-C10-alkenylene-Y, C3-C10-cycloalkylene-Y and C3-C10-cycloalkenylene-Y, the substituents of which are selected from the group consisting of halogens, CN, N3, CF3, C1-C6-alkyl and C1-C6-alkoxy;
• E is O or S;
• Y is selected from the group consisting of hydrogen;
• and unsubstituted and at least monosubstituted C1-C10-alkyl, aryl, heterocyclyl, aryl-(C1-C10-alkylene)- and heterocyclyl-(C1-C10-alkylene), the substituents of which are selected from the group consisting of halogens, CN, N3, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heterocyclyl, C1-C6-alkoxy, NH2, (C1-C6-alkyl)amino, di(C1-C6-alkyl)amino, C1-C6-alkoxy-(C1-C6-alkylene)-, nitro, carboxy, carbalkoxy, carboxy-(C1-C6-alkylene)-, carbalkoxy-(C1-C6-alkylene)-, hydroxy, hydroxy-(C1-C6-alkylene)-, mercapto, (C1-C6-alkyl)thio, mercapto-(C1-C6-alkylene)-, C1-C6-alkyl substituted by at least one halogen, (C1-C6-alkyl)sulfonyl-,aminosulfonyl-, (C1-C6-alkyl)aminosulfonyl-, (C1-C6-alkyl)sulfonylamido-, (C1-C6-alkyl)-sulfonyl-(C1-C6-alkylene)amino-, HO3S—(C1-C6-alkylene)-, carbamoyl-(C1-C6-alkylene)-, (C1-C6-alkyl)-carbamoyl, (C1-C6-alkyl)-C(O)O—, (C1-C6-alkyl)-CO—, —SO3H and carbamoyl;
• T is a residue selected from the group consisting of C1-C10-alkyl, C1-C10-cycloalkyl, aryl-(C1-C10-alkylene)- and heterocyclyl-(C1-C10-alkylene), which residues are monosubstituted by halogen or OR2, and which residues can be optionally substituted by at least one further substituent selected from the group consisting of halogens, CN, N3, mercapto, NH2, nitro, hydroxy, unsubstituted and at least monosubstituted C1-C6-alkyl, C1-C6-alkoxy, (C1-C6-alkyl)amino, (C1-C6-alkyl)thio, aryl and heterocyclyl, the substituents of which are selected from the group consisting of halogens, CN, N3, C1-C3-alkyl, C1-C3-alkoxy and hydroxy;
• R2 is C1-C10-alkyl substituted by at least one halogen;
• A is hydrogen, C1-C10-alkyl, hydroxy-(C1-C10-alkylene)-, C1-C10-alkoxy-(C1-C10-alkylene)-, or OR′;
• B ist hydrogen, C1-C10-alkyl, hydroxy-(C1-C10-alkylene)-, C1-C10-alkoxy-(C1-C10-alkylene)-, or OR″;
• R′ and R″ are independently selected from the group consisting of hydrogen, C1-C6-alkyl, aryl-(C1-C6-alkylene)-, (C1-C6-alkyl)-CO, carbalkoxy, aryl-(C1-C6-alkylene)-CO—, and aryl-O—CO—;
• when A and B are OR′ and OR″, respectively, R′ and R″ together may form a substituent selected from the group consisting of
• RC is hydrogen or C1-C6-alkyl;
• Rd and Re are independently hydrogen, C1-C10-alkyl, or together with the carbon atom to which they are attached may form a 1,1-cycloalkyl group;
• heterocyclyl is a 4 to 10-membered, mono- or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S;
• aryl is phenyl, indan-1-yl, indan-2-yl, naphth-1-yl or naphth-2-yl;
• or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, or an N-oxide thereof.